SEQ
  • Bienvenido a la SEQ
    • Junta Directiva
    • Misión, visión y valores
    • Elecciones para la renovación Junta Directiva de la SEQ 2021
    • Estatutos SEQ
    • Colaboradores
    • Hazte socio
    • Contacto
  • Noticias
    • Cursos
    • Agenda de Congresos
    • Sociedades Científicas
    • Revistas Científicas
  • Actividades
    • Reuniones
    • Congresos
    • Cursos de Formación
  • Revista Española de Quimiopterapia
    • Journal info
    • Advance articles
    • Search an issue
    • Submission guidelines
    • Submit a manuscript
  • Documentos
    • Documentos de Consenso
    • Libros y monografías
    • Revista Infección y Vacunas
    • Informes
    • Declaraciones
    • Base de Datos
    • Otros
      • Curiosidades
      • Narraciones Infecciosas
  • Click to open the search input field Click to open the search input field Buscar
  • Menú Menú
Abstract, Abstract 2024

Rev Esp Quimioter 2024, 37(5): 369-386

New materials and complications of prostheses in humans: situation in Spain

MARÍA VALLET-REGÍ, ARÍSTIDES DE ALARCÓN, ENRIQUE GÓMEZ BARRENA, JOSEP A. PLANELL, JACOBO SILVA, EMILIO BOUZA

Published: 23 May 2024

http://www.doi.org/10.37201/req/039.2024

Prostheses or implantable medical devices (IMDs) are parts made of natural or artificial materials intended to replace a body structure and therefore must be well tolerated by living tissues. The types of IMDs currently available and usable are very varied and capable of replacing almost any human organ. A high but imprecise percentage of Spaniards are carriers of one or more IMDs to which they often owe their quality of life or survival. IMDs are constructed with different types of materials that are often combined in the same prosthesis. These materials must combine harmlessness to human tissues with high wear resistance. Their durability depends on many factors both on the host and the type of prosthesis, but the vast majority last for more than 10-15 years or remain in function for the lifetime of the patient. The most frequently implanted IMDs are placed in the heart or great vessels, joints, dental arches or breast and their most frequent complications are classified as non-infectious, particularly loosening or intolerance, and infectious. Complications, when they occur, lead to a significant increase in morbidity, their repair or replacement multiplies the health care cost and, on occasions, can cause the death of the patient. The fight against IMD complications is currently focused on the design of new materials that are more resistant to wear and infection and the use of antimicrobial substances that are released from these materials. Their production requires multidisciplinary technical teams, but also a willingness on the part of industry and health authorities that is not often found in Spain or in most European nations. Scientific production on prostheses and IMD in Spain is estimated to be less than 2% of the world total, and probably below what corresponds to our level of socio-economic development. The future of IMDs involves, among other factors, examining the potential role of Artificial Intelligence in their design, knowledge of tissue regeneration, greater efficiency in preventing infections and taking alternative treatments beyond antimicrobials, such as phage therapy. For these and other reasons, the Ramón Areces Foundation convened a series of experts in different fields related to prostheses and IMDs who answered and discussed a series of questions previously formulated by the Scientific Council. The following lines are the written testimony of these questions and the answers to them.

Rev Esp Quimioter 2024;  37(5): 369-386 [Full-text PDF]


</a

22 mayo, 2024/por Luis Alou
Compartir esta entrada
  • Compartir en Facebook
  • Compartir en X
  • Compartir en LinkedIn
  • Compartir por correo
https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png 0 0 Luis Alou https://seq.es/wp-content/uploads/2017/10/LOGO-SEQ-800X400.png Luis Alou2024-05-22 11:09:112024-09-10 08:54:37Rev Esp Quimioter 2024, 37(5): 369-386

REVISTA ESPAÑOLA DE QUIMIOTERAPIA

  • Journal Info
  • Advance Articles
  • Issues
  • Submission guidelines
  • Submit a manuscript

Contacto

Telf.: 913 94 15 12
Email: [email protected]

Política de privacidad

Aviso Legal
Política de Privacidad
Política de Cookies

Tweets by TwitterDev
© Copyright - Sociedad Española de Quimioterapia - Enfold Theme by Kriesi
  • Link to Facebook
  • Link to X
  • Link to LinkedIn
Link to: Rev Esp Quimioter 2024, 37(5): 369-386 Link to: Rev Esp Quimioter 2024, 37(5): 369-386 Rev Esp Quimioter 2024, 37(5): 369-386 Link to: Rev Esp Quimioter 2024, 37(4): 351-355 Link to: Rev Esp Quimioter 2024, 37(4): 351-355 Rev Esp Quimioter 2024, 37(4): 351-355
Desplazarse hacia arriba Desplazarse hacia arriba Desplazarse hacia arriba

Utilizamos cookies propias y de terceros para garantizar el funcionamiento de la web, medir su uso y mejorar nuestros servicios. Puede aceptar todas las cookies, rechazar las no necesarias o configurar sus preferencias. Política de cookies

Configurar cookies

Necesarias para que la web funcione correctamente. No se pueden desactivar desde este panel.

Ayudan a medir el uso del sitio y mejorar sus contenidos.

Permiten publicidad, medición de campañas o personalización de anuncios.

Guardan preferencias o permiten contenido externo no necesario.